Outlook Therapeutics, Inc. — Form 10-Q Summary
Reporting period: Three and six months ended March 31, 2023 (fiscal second quarter). The company is a clinical-stage biopharmaceutical developer focused on ONS-5010 (bevacizumab-vikg), an investigational ophthalmic treatment for wet age-related macular degeneration (wet AMD) and other retinal diseases. It has not generated product revenue.
Key financial metrics
| Metric | Three months ended Mar. 31, 2023 | Six months ended Mar. 31, 2023 | Comparable 2022 period |
|---|---|---|---|
| Revenue | No product revenue | No product revenue | No product revenue |
| Research and development expense | $0.5 million | $10.4 million | $12.2 million and $22.1 million, respectively |
| General and administrative expense | $6.3 million | $12.1 million | $6.7 million and $10.0 million, respectively |
| Net loss | $6.7 million | $25.3 million | $19.7 million and $34.2 million, respectively |
| Net loss per share, basic and diluted | $0.03 | $0.10 | $0.09 and $0.17, respectively |
| Net cash used in operations | Not separately presented | $17.0 million | $25.3 million |
| Cash and cash equivalents | $43.6 million at Mar. 31, 2023 | $58.4 million at Mar. 31, 2022 | |
| Debt | $31.8 million carrying value of convertible note at Mar. 31, 2023; $35.1 million principal, accrued interest and exit fees stated as due | $10.9 million current debt at Sept. 30, 2022 |
Margins are not meaningful because the company has no product sales. At March 31, 2023, current assets were $53.1 million and current liabilities were $43.5 million. The filing reports an accumulated deficit of $434.3 million and substantial doubt about the company’s ability to continue as a going concern.
Material changes and financing
- Quarterly net loss narrowed year over year, primarily alongside lower R&D expense. R&D expense fell by $11.7 million in the quarter and six-month comparison, substantially reflecting refunds of waived FDA BLA submission fees, prior-period BLA filing fees, lower stock-based compensation, and completed clinical and manufacturing activities.
- For the six months, G&A expense increased $2.2 million, mainly from professional fees for pre-launch preparation. The company said it was preparing for a potential ONS-5010 launch.
- Operating cash use was $17.0 million for the six months. Financing activities provided $43.2 million, including proceeds from a December 2022 equity offering and a new convertible note; cash increased $26.2 million from September 30, 2022.
- Common shares outstanding rose to 256.7 million from 227.3 million at September 30, 2022. The December 2022 registered direct offering generated approximately $24.0 million net; the company also issued 28.5 million shares. The filing reports 256.7 million shares outstanding as of May 10, 2023.
Outlook, risks and unusual items
- The FDA accepted the ONS-5010 BLA for filing and set an August 29, 2023 review decision goal date. The EMA validated the MAA for review, with a decision expected in early 2024. Management expected March cash to fund operations through the anticipated FDA decision in the third calendar quarter of 2023 and potentially through the fourth quarter; it said additional financing would be required.
- Management is considering equity or debt financing, licensing, marketing arrangements and collaborations. It cautioned that funding may not be available on acceptable terms or at all; failure to secure capital could force delays, reductions or discontinuation of programs, or other restructuring actions.
- The December 2022 unsecured convertible note has a $31.8 million face amount, 9.5% annual interest and a January 1, 2024 maturity. It permits lender conversion beginning April 1, 2023, includes conversion-price adjustment provisions, a 7.5% fee on cash payments, and potential default penalties, including 22% annual interest after an event of default. The lender also has specified consent and participation rights over future financing.
- The company terminated its at-the-market offering agreement effective May 15, 2023, after the reporting date. The filing states no shares were sold under it during the quarter; 895,391 shares were sold during the six-month period.
- Management reported effective disclosure controls and procedures and no material pending legal proceedings. The company disclosed macroeconomic, market-access, regulatory, manufacturing, clinical-development, competition and commercialization risks.
Most important facts for investors to verify
- Whether FDA review of the BLA remains on schedule and the outcome of the August 29, 2023 goal date; also verify any subsequent FDA requests or approval conditions.
- Cash runway, subsequent financing, and the company’s ability to meet the note’s January 2024 maturity and other obligations.
- Current note balance and conversion or repayment terms, including any adjustments, trigger events, defaults, or dilution from conversion.
- Commercial launch readiness, expected costs, manufacturing capacity, and whether strategic partnerships or additional capital have been secured.
- Whether the EMA review timetable and the anticipated early-2024 decision remain current.